Eric Chatelain

Eric Chatelain serves as the Head of Drug Discovery at the Drugs for Neglected Diseases initiative (DNDi), where responsibilities include leading translational drug development for COVID-19 and managing efforts in Chagas disease and visceral leishmaniasis. With extensive experience in project management and drug discovery, Eric has been pivotal in defining public health research strategies, improving in vivo models, and overseeing global project teams in collaboration with various partners. Prior to DNDi, Eric held leadership positions at Galderma, where responsibilities encompassed preclinical research and biosafety management, and at prominent research institutions including the Friedrich Miescher Institute and Cancer Research UK, focusing on gene therapy and growth factor research. Eric holds a Ph.D. in Biochemistry and Molecular Biology, along with business management credentials.